A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis.

Abstract	Twenty-six patients with perennial rhinorrhea were treated by Atrovent, the anticholinergic agent, or placebo in a randomized double-blind crossover trial. The severity and duration of rhinorrhea were significantly reduced by Atrovent. Local side effects were more frequent with the active drug. These were reduced in a later open trial by a reduction in dosage.
Authors	A Knight, F Kazim, V A Salvatori
Journal	Annals of allergy (Ann Allergy) Vol. 57 Issue 5 Pg. 348-54 (Nov 1986) ISSN: 0003-4738 [Print] United States
PMID	2946252 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Atropine Derivatives Ipratropium
Topics	Administration, Intranasal Adolescent Adult Atropine Derivatives (therapeutic use) Clinical Trials as Topic Double-Blind Method Female Humans Ipratropium (administration & dosage, adverse effects, therapeutic use) Male Middle Aged Random Allocation Rhinitis, Vasomotor (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!